The Liver Meeting 2020-Alcohol-associated Liver Disease SIG Clinical Unmet Needs in Alcohol-associated Liver Disease (ALD)

Alcohol-associated Liver Disease SIG Clinical Unmet Needs in Alcohol-associated Liver Disease (ALD)

Video Transcription

Video Summary

The video discusses the potential of fecal microbiota transplantation as a therapeutic approach for alcohol-associated liver disease (ALD) and the need for further research. Elevated cytokine levels, especially TNF-alpha, IL-6, and IL-1 beta, in patients with alcoholic hepatitis indicate an inflammatory response that can impact disease severity. Modulating these cytokines could improve outcomes. Dysregulation of bile acids is also linked to ALD pathogenesis, suggesting correcting these abnormalities could be a treatment target. The interaction between the microbiome, cytokines, and bile acids is crucial in ALD development. The importance of integrated care involving hepatologists, addiction specialists, and psychiatrists for ALD patients is highlighted. Liquid biopsies and non-invasive biomarkers are being developed for ALD diagnosis. Emerging therapies targeting gut microbiomes, cytokines, bile acids, and oxysterols are being explored. Consideration of early liver transplantation for severe alcoholic hepatitis is discussed, along with evolving criteria for patient selection for transplantation. Collaboration, education, and evidence-based interventions are emphasized in managing ALD effectively.

Keywords

Fecal microbiota transplantation

Alcohol-associated liver disease

Cytokine levels

TNF-alpha

IL-6

IL-1 beta

Inflammatory response

Bile acids

Microbiome

Integrated care

Liquid biopsies

Non-invasive biomarkers